Search results

1203 results

Sorted by Relevance . Sort by Date

  1. Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For acute iliofemoral DVT the evidence on efficacy is limited in quality and quantity, therefore this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG651/1 Question Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis

  2. Endocrine cancers

    Everything NICE has said on endocrine cancers in an interactive flowchart

  3. Cervical cancer

    Everything NICE has said on screening and managing cervical cancer in an interactive flowchart

  4. Gastrointestinal cancers

    Everything NICE has said on gastrointestinal cancers in an interactive flowchart

  5. Pancreatic cancer

    Everything NICE has said on pancreatic cancer in adults in an interactive flowchart

  6. Sarcoma

    Everything NICE has said on sarcoma in an interactive flowchart

  7. Brain tumours and metastases

    Everything NICE has said on brain tumours in adults, including cancer, in an interactive flowchart

  8. Renal cancer

    Everything NICE has said on renal (kidney) cancer in an interactive flowchart

  9. Bladder cancer

    Everything NICE has said on bladder cancer in adults in an interactive flowchart

  10. Upper aerodigestive tract cancer

    Everything NICE has said on assessing and managing upper aerodigestive tract cancer in young people and adults in an interactive flowchart

  11. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

  12. Skin cancer

    Everything NICE has said on skin cancers, including melanoma, basal cell carcinoma and squamous cell carcinoma in an interactive flowchart

  13. Neutropenic sepsis

    Everything NICE has said on preventing, identifying and managing neutropenic sepsis in children, young people and adults in an interactive flowchart

  14. Board committees

    Audit and risk committee The audit and risk committee provides an independent, objective review of arrangements for internal control within NICE. The

  15. NICE chairman Sharmila Nebhrajani begins her new role

    NICE is delighted to announce that today (26 May 2020) Sharmila Nebhrajani, OBE, has taken up her position as its new chairman following her appointment by the Secretary of State for Health and Social Care and an independent open recruitment process.

  16. Hypertension in pregnancy

    Everything NICE has said on diagnosing and managing hypertension in pregnancy in an interactive flowchart

  17. Preventing type 2 diabetes

    Everything NICE has said on preventing type 2 diabetes in an interactive flowchart

  18. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)

    The purpose of this guideline is to maximise the safety of children and young people who are immunocompromised during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  19. Diagnostics guidance static list

    The following published diagnostics assessments have been transferred to the static list. Guidance is moved to the static list following consultation

  20. EBSCO

    Provider name: EBSCO Lot details Lot 1 - Databases, Aggregated Evidence Resource Summaries, Point of Care (PoC) Tools Lot 2 - Electronic

  21. COVID-19 rapid guideline: dialysis service delivery (NG160)

    The purpose of this guideline is to maximise the safety of patients on dialysis, while protecting staff from infection. It will also enable dialysis services to make the best use of NHS resources and match the capacity of dialysis services to patient needs if these become limited because of the COVID-19 pandemic.

  22. Sunlight exposure: risks and benefits

    Everything NICE has said on how to communicate the risks and benefits of natural sunlight exposure in an interactive flowchart

  23. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  24. Scholars

    Scholarships are one year opportunities to improve quality of care and contribute to your professional development

  25. STA timeline

    A step-by-step timeline of the process we used to develop single technology appraisals (STA)

  26. MTA process timeline

    These are the main stages in multiple technology appraisals process. Timings are approximate. For a full description of the appraisal process see our

  27. COVID-19 rapid guideline: interstitial lung disease (NG177)

    The purpose of this guideline is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis and pulmonary sarcoidosis, during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  28. COVID-19 rapid guideline: chronic kidney disease (NG176)

    The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  29. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

  30. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

  31. Brand guidelines

    This is an overview of the NICE brand identity incorporating who we are, what we do, and the values underpinning our work. Who we are NICE is the...

  32. Pneumonia

    Everything NICE has said on assessing and managing community- and hospital-acquired pneumonia in an interactive flowchart

  33. Past appeals and decisions

    Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TA111 Alzheimer´s

  34. Acute upper gastrointestinal bleeding

    Everything NICE has said on risk assessment and management of acute upper gastrointestinal bleeding in people 16 years and older in an interactive flowchart

  35. Transition from children's to adults' services

    Everything NICE has said on the transition from children's to adults' services for young people in health or social care in an interactive flowchart